93 related articles for article (PubMed ID: 17399972)
1. Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists.
Santus P; Centanni S; Morelli N; Di Marco F; Verga M; Cazzola M
Respir Med; 2007 Aug; 101(8):1798-803. PubMed ID: 17399972
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD.
Andò F; Ruggeri P; Girbino G; Cazzola M
Respir Med; 2008 Jun; 102(6):815-8. PubMed ID: 18343646
[TBL] [Abstract][Full Text] [Related]
3. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.
Di Marco F; Verga M; Santus P; Morelli N; Cazzola M; Centanni S
Respir Med; 2006 Nov; 100(11):1925-32. PubMed ID: 16626956
[TBL] [Abstract][Full Text] [Related]
4. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
5. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
6. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.
Richter K; Stenglein S; Mücke M; Sieder C; Schmidtmann S; Harnest U; Weidinger G; Magnussen H
Respiration; 2006; 73(4):414-9. PubMed ID: 16534180
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
8. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
9. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
10. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Cazzola M; Noschese P; Salzillo A; De Giglio C; D'Amato G; Matera MG
Respir Med; 2005 May; 99(5):524-8. PubMed ID: 15823447
[TBL] [Abstract][Full Text] [Related]
11. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
12. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
13. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
14. Short term effect of a single dose of formoterol or tiotropium on the isolated nocturnal hypoxemia in stable COPD patients: a double blind randomized study.
Sposato B; Franco C
Eur Rev Med Pharmacol Sci; 2008; 12(3):203-11. PubMed ID: 18700693
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis.
Wang J; Jin D; Zuo P; Wang T; Xu Y; Xiong W
Respirology; 2011 Feb; 16(2):350-8. PubMed ID: 21138499
[TBL] [Abstract][Full Text] [Related]
16. [Indacaterol--a new hope for maximising bronchodilation?].
Mihălţan F
Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
[TBL] [Abstract][Full Text] [Related]
17. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
18. Effects of tiotropium and formoterol on quiet breathing pattern assessed by optoelectronic plethysmography in COPD patients: a pilot study.
Dal Negro RW; Turati C; Micheletto C; Menegoni F
Ther Adv Respir Dis; 2012 Apr; 6(2):97-105. PubMed ID: 22250038
[TBL] [Abstract][Full Text] [Related]
19. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
20. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
